EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives

Miao Lv, Simin Guo, Hexian Yang, Yongjian Wang, Yiming Li, Yang Li, Hong Yi, Hongwei He iD, Zhuorong Li

Molecules · 2024

DOI: 10.3390/molecules29194774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Miao Lv und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Aspartic Acid, Collagen Type I. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis plays an important role in the progression of liver disease, but there is a severe shortage of direct and efficacious pharmaceutical clinical interventions. Literature research indicates that aspartic acid exhibits hepatoprotective properties. In this paper, 32 target compounds were designed and synthesized utilizing aspartic acid as the lead compound, of which 22 were new compounds not reported in the literature. These compounds were screened for their inhibitory effects on the COL1A1 promoter to assess in vitro anti-liver fibrosis activity and summarized structure–activity relationships. Four compounds exhibited superior potency with inhibition rates ranging from 66.72% to 97.44%, substantially higher than EGCG (36.46 ± 4.64%) and L-Asp (11.33 ± 0.35%). In an LPS-induced inflammation model of LX-2 cells, both 41 and 8a could inhibit the activation of LX-2 cells, reducing the expression of COL1A1, fibronectin, and α-SMA. Upon further investigation, 41 and 8a ameliorated liver fibrosis by inhibiting the IKKβ-NF-κB signaling pathway to alleviate inflammatory response. Overall, the study evaluated the anti-liver fibrosis effects of aspartic acid derivatives, identified the potency of 41, and conducted a preliminary exploration of mechanisms, laying the foundation for the discovery of novel anti-liver fibrosis agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisAspartic AcidCollagen Type IHumansCell LineNF-kappa BStructure-Activity RelationshipSignal TransductionCollagen Type I, alpha 1 ChainHepatic Stellate Cells

Stichwörter der Autor:innen

IKKβ-NF-κB signaling pathwayaspartic acidliver fibrosis

Substanzen

Aspartic AcidCollagen Type INF-kappa BCollagen Type I, alpha 1 Chain

Autor:innen und Institutionen

  • Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

ORCID-Profile: Hongwei He

Förderung

  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation

Zitieren

APA

Lv, M., Guo, S., Yang, H., Wang, Y., Li, Y., Li, Y., Yi, H., He, H., & Li, Z. (2024). Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives. Molecules. https://doi.org/10.3390/molecules29194774

Vancouver

Lv M, Guo S, Yang H, Wang Y, Li Y, Li Y, et al. Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives. Molecules. 2024. doi:10.3390/molecules29194774

BibTeX
@article{Lv2024,
  author = {Lv, Miao and Guo, Simin and Yang, Hexian and Wang, Yongjian and Li, Yiming and Li, Yang and Yi, Hong and He, Hongwei and Li, Zhuorong},
  title = {Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29194774}
}
Kostenlos starten →